department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

CANAGLIFLOZIN · pharmadog

pharmadog
drugs
CANAGLIFLOZIN

drug

patient view →

CANAGLIFLOZIN

Marketedupdated 2mo ago

by Johnson & Johnson Innovative Medicine

Approved

community read0 votes

indications

investigational

Type 2 Diabetes

all catalysts(2)

approval · 2

News(0)

no news has mentioned this drug yet

brand

CANAGLIFLOZIN

generic

CANAGLIFLOZIN

indication

Type 2 Diabetes

phase

marketed

CANAGLIFLOZIN — FDA approval

CANAGLIFLOZIN — FDA approval

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Jul 14, 2027

~1.0 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (12)

Aug 26, 2029patentUS 7943582*PED3.1y
Aug 26, 2029patentUS 7943582*PED3.1y
Feb 26, 2029compositionUS 79435822.6y
Feb 26, 2029compositionUS 79435822.6y
Jun 3, 2028patentUS 8513202*PED1.9y
Jun 3, 2028patentUS 8513202*PED1.9y
Jan 14, 2028patentUS 7943788*PED1.5y
Jan 14, 2028patentUS 7943788*PED1.5y
Dec 3, 2027compositionUS 85132021.4y
Dec 3, 2027compositionUS 85132021.4y
Jul 14, 2027compositionUS 79437881.0y
Jul 14, 2027compositionUS 79437881.0y

FDA exclusivities (4)

Jun 18, 2028PEDPediatric (6mo bonus)2.0y
Jun 18, 2028PEDPediatric (6mo bonus)2.0y
Dec 18, 2027NPPNew Product (3y)1.4y
Dec 18, 2027NPPNew Product (3y)1.4y

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 3

tagApproval4 co-mentions · 2 sources
tagSmall Molecule2 co-mentions · 2 sources
companyAurobindo Pharma Ltd1 co-mentions · 1 sources

Trials studying CANAGLIFLOZIN

phase4Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellituscompletedn=146
phase4Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellituscompletedn=139
phase4Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellituscompletedn=71
phase3Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)completedn=138
phase3Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathycompletedn=308
phase3Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)completedn=154
phase3Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetescompletedn=153
—A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Diseasecompletedn=714,582

more trials →